

MagNA Pure 96 system protocols



| Target | Protocol name | Input sample type and sample volumes | | | | | | | | | | | | | Elution volume | Run time*** (h:mm) |
|---|---|--|------------------|---------------|-------|-------|------|--------|-----|-------|-------|----------------|---------------------|---------|-----------------|--------------------|
| | | Whole blood | Plasma (citrate) | Plasma (EDTA) | Serum | Swabs | BAL* | Sputum | CSF | Urine | Stool | Cultured cells | Fresh-frozen tissue | FFPET** | | |
| Bacterial, fungal and viral NA | Pathogen Universal 200 ¹ | 200 µL | | | | | | | | | | | | | 50, 100 µL | 1:00 |
| | Fast Viral NA SV ¹ | 200 µL | | | | | | | | | | | | | | 0:30 |
| | Fast Viral NA ext lys SV ¹ | 450 µL lysate from 200 µL | | | | | | | | | | | | | | 0:30 |
| | Viral NA Plasma SV ¹ | 50, 100, 200 µL | | | | | | | | | | | | | | 1:00 |
| | Viral NA Plasma ext lys SV ¹ Protocol optimized with external lysis reagent | 350, 450 µL lysate from 100, 200 µL sample | | | | | | | | | | | | | | 1:00 |
| | Viral NA Universal SV ¹ | 50, 100, 200 µL | | | | | | | | | | | | | | 1:00 |
| | Pathogen Universal 500 ² | 500 µL | | | | | | | | | | | | | | 1:30 |
| | Pathogen Universal 1000 ² | 1,000 µL | | | | | | | | | | | | | | 1:40 |
| | Viral NA Plasma LV ² | 500 µL | | | | | | | | | | | | | | 1:10 |
| | Viral NA Plasma LV 1000 ² | 1,000 µL | | | | | | | | | | | | | | 1:20 |
| | Viral NA Plasma ext lys LV ² Protocol optimized with external lysis reagent | 1,000 µL lysate from 500 µL sample | | | | | | | | | | | | | | 1:10 |
| | Viral NA Universal LV ² | 500 µL | | | | | | | | | | | | | | 1:30 |
| Viral NA Universal LV 1000 ² | 1,000 µL | | | | | | | | | | | | | 1:30 | | |
| Genomic DNA | DNA Blood SV ¹ Recommended for elution of predominantly double-stranded DNA | 50, 100, or 200 µL whole blood ≤2 x 10 ⁶ cells/samples | | | | | | | | | | | | | 50, 100 µL | 1:00 |
| | DNA Blood ext lys SV ¹ Protocol optimized with external lysis reagent | 300, 350, or 450 µL lysate from 50, 100, or 200 µL sample | | | | | | | | | | | | | | 0:50 |
| | DNA Cells SV ¹ | Up to 5 x 10 ⁶ cultured cells in 200 µL PBS | | | | | | | | | | | | | 100 µL | 1:00 |
| | DNA Tissue SV ¹ | Up to 5 mg in 200 µL | | | | | | | | | | | | | 100, 200 µL | 1:20 |
| | DNA FFPE SV ¹ | 200 µL lysate from 2 x 5 µm sections | | | | | | | | | | | | | 50, 100 µL | 1:00 |
| | DNA Blood LV ² | 500 µL (≤1 x 10 ⁷ cells/ml) | | | | | | | | | | | | | 100, 200 µL | 1:20 |
| | DNA Blood LV 1000 ² | 1,000 µL (≤1 x 10 ⁷ cells/ml) | | | | | | | | | | | | | | 1:30 |
| | DNA Blood ext lys LV ² Protocol optimized with external lysis reagent | 1,000 µL lysate from 500 µL sample (≤1 x 10 ⁷ cells/mL) | | | | | | | | | | | | | 100, 200 µL | 0:50 |
| | DNA Cells LV ² | Up to 1 x 10 ⁶ cultured cells in 200 µL PBS | | | | | | | | | | | | | 100, 200 µL | 1:20 |
| | DNA Tissue LV ² | Up to 25mg in 200 µL | | | | | | | | | | | | | 200 µL | 1:20 |
| Cell-free NA | cfNA ss 2000 ² Protocol optimized for single-stranded DNA | 2,000 µL | | | | | | | | | | | | | 50, 100 µL | 2:00 |
| | cfNA ss 4000 ² Protocol optimized for single-stranded DNA | 4,000 µL | | | | | | | | | | | | | | 2:20 |
| | cfNA ds 2000 ² Protocol optimized for double-stranded DNA | 2,000 µL | | | | | | | | | | | | | 100, 200 µL | 2:20 |
| | cfNA ds 4000 ² Protocol optimized for double-stranded DNA | 4,000 µL | | | | | | | | | | | | | | 2:50 |
| Total RNA | Cellular RNA LV ³ | Up to 1 x 10 ⁶ cultured cells in 200 µL PBS | | | | | | | | | | | | | 50, 100, 200 µL | 1:30 |
| | RNA Blood LV 400 ³ | 900 µL stabilized whole blood from 400 µL whole blood | | | | | | | | | | | | | | 50, 100, 200 µL |
| | RNA Blood LV 800 ³ | 1,800 µL stabilized whole blood from 800 µL whole blood | | | | | | | | | | | | | 100, 200 µL | 1:30 |
| | RNA PAXgene LV ³ | PAXgene pellet in 400 µL PBS | | | | | | | | | | | | | 100, 200 µL | 1:30 |
| | RNA PAXgene Half Tube LV ³ | Half PAXgene pellet in 200 µL PBS | | | | | | | | | | | | | 50, 100 µL | 1:30 |
| | RNA Tissue FF Standard LV ³ | Up to 10 mg in 350 µL | | | | | | | | | | | | | 50, 100, 200 µL | 1:30 |
| | RNA Tissue FF High LV ³ | Up to 25 mg in 700 µL | | | | | | | | | | | | | 100, 200 µL | 1:30 |
| | RNA Tissue FFPE LV ³ | 150 µL lysate from 2 x 5 µm sections | | | | | | | | | | | | | 50, 100 µL | 1:30 |
| Liquid handling | Sample Transfer to the processing cartridge | 50 µL to 1,000 µL | | | | | | | | | | | | | | N/A |
| | Archive Plate Transfer For archiving purposes | | | | | | | | | | | | | | | |
| | PCR Setup with Mixing | 5 µL to 200 µL | | | | | | | | | | | | | | |
| | PCR Setup without Mixing | | | | | | | | | | | | | | | |

¹ MagNA Pure 96 DNA and Viral NA Small Volume Kit (cat. no. 06 543 588 001)
² MagNA Pure 96 DNA and Viral NA Large Volume Kit (cat. no. 06 374 891 001)
³ MagNA Pure 96 Cellular RNA Large Volume Kit³ (cat. no. 05 467 535 001)

*BAL - Bronchoalveolar Lavage
 **FFPET - formalin-fixed paraffin-embedded tissue
 ***These times are approximate and should only be used as a guidance.

¹ For general laboratory use.
² For life science research only.
³ Not for use in diagnostic procedures.

To get better results, Roche provides various External Lysis Buffers: MagNA Pure cfNA Buffer Set¹ (Cat. no. 07 794 398 001), MagNA Pure External Lysis Buffer (Cat. no. 06 374 913 001), MagNA Pure Bacterial Lysis Buffer (Cat. no. 06 374 921 001), MagNA Pure DNA Tissue Lysis Buffer (Cat. no. 06 640 702 001), MagNA Pure FFPET Buffer Set¹ (Cat. no. 08 447 144 001), MagNA Pure RNA Tissue Lysis Buffer¹ (Cat. no. 03 604 721 001), and S.T.A.R. Buffer¹ (Cat. no. 03 335 208 001). Please refer to the instructions for use manual for more details.

Start here. Go Anywhere.



All MagNA Pure 96 kits, consumables, and accessories are for in vitro diagnostic use unless otherwise noted.
 MAGNA PURE is a registered trademark of Roche.
 All other product names and trademarks are the property of their respective owners.
 © 2026 Roche Molecular Systems, Inc. All rights reserved.

Published by
 Roche Molecular Systems, Inc
 4300 Hacienda Drive
 Pleasanton, CA 94588 USA